Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 5/2009

01-05-2009 | Breast Oncology

Validation of a Nomogram to Predict the Risk of Nonsentinel Lymph Node Metastases in Breast Cancer Patients with a Positive Sentinel Node Biopsy: Validation of the MSKCC Breast Nomogram

Authors: R. F. D. van la Parra, MD, M. F. Ernst, MD, PhD, J. L. B. Bevilacqua, MD, PhD, S. J. J. Mol, MD, K. J. Van Zee, MS, MD, J. M. Broekman, MD, PhD, K. Bosscha, MD, PhD

Published in: Annals of Surgical Oncology | Issue 5/2009

Login to get access

Abstract

Background

Completion axillary lymph node dissection (ALND) remains the standard of care for patients with disease-positive sentinel lymph nodes (SLN). However, approximately two-thirds will have no additional disease-positive nodes. To identify the patient’s individual risk for non-SLN metastases, the Memorial Sloan-Kettering Cancer Center (MSKCC) developed a nomogram.

Methods

The records of 182 breast cancer patients who underwent SLN and ALND were selected. Serial hematoxylin and eosin (HE) analysis and immunohistochemistry were routinely performed on each sentinel node. For application of the nomogram, the detection method was assigned in two ways: for all metastases visible by serial HE, the method of detection was scored as “serial HE” (method 1), independent of the tumor size, and by a combination of size and staining method (method 2); so macrometastasis were scored as detected by routine HE, micrometastasis by serial HE, and isolated tumor cells by immunohistochemistry. A receiver operating characteristic curve (ROC) was drawn, and the area under the curve was calculated to assess the discriminative power of the nomogram.

Results

The area under the ROC was .71 (range, .64–.79) according to method 1 and .75 (range, .67–.88) according to method 2.

Conclusions

Because the variable “method of detection” in the MSKCC nomogram is a surrogate for SLN metastasis size, the size category of the SLN metastasis can be used in applying the nomogram to patients in whom the SLN histologic analysis is performed by a much different procedure than that used to develop the MSKCC nomogram. This results in an improved predictive accuracy.
Literature
1.
CBO. Richtlijn behandeling van het mammacarcinoom. Amsterdam, The Netherlands: Van Zuiden Communications BV; 2005.
2.
Bolster MJ, Peer PG, Bult P, et al. Risk factors for non-sentinel lymph node metastases in patients with breast cancer. The outcome of a multi-institutional study. Ann Surg Oncol. 2007;14:181–9.PubMedCrossRef
3.
Changsri C, Prakash S, Sandweiss L, Bose S. Prediction of additional axillary metastasis of breast cancer following sentinel lymph node surgery. Breast J. 2004;10:392–7.PubMedCrossRef
4.
Chu KU, Turner RR, Hansen NM, Brennan MB, Bilchik A, Giuliano AE. Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection? Ann Surg. 1999;229:536–41.PubMedCrossRef
5.
Cserni G. Sentinel lymph-node biopsy-based prediction of further breast cancer metastases in the axilla. Eur J Surg Oncol. 2001;27:532–8.PubMedCrossRef
6.
Cserni G, Burzykowski T, Vinh-Hung V, et al. Axillary sentinel node and tumour-related factors associated with non-sentinel node involvement in breast cancer. Jpn J Clin Oncol. 2004;34:519–24.PubMedCrossRef
7.
Farshid G, Pradhan M, Kollias J, Gill PG. A decision aid for predicting non-sentinel node involvement in women with breast cancer and at least one positive sentinel node. Breast. 2004;13:494–501.PubMedCrossRef
8.
Fleming FJ, Kavanagh D, Crotty TB, et al. Factors affecting metastases to non-sentinel lymph nodes in breast cancer. J Clin Pathol. 2004;57:73–6.PubMedCrossRef
9.
Fournier K, Schiller A, Perry RR, Laronga C. Micrometastasis in the sentinel lymph node of breast cancer does not mandate completion axillary dissection. Ann Surg. 2004;239:859–63.PubMedCrossRef
10.
Goyal A, Douglas-Jones A, Newcombe RG, Mansel RE. Predictors of non-sentinel lymph node metastasis in breast cancer patients. Eur J Cancer. 2004;40:1731–7.PubMedCrossRef
11.
Hwang RF, Krishnamurthy S, Hunt KK, et al. Clinicopathologic factors predicting involvement of nonsentinel axillary nodes in women with breast cancer. Ann Surg Oncol. 2003;10:248–54.PubMedCrossRef
12.
Menes TS, Tartter PI, Mizrachi H. Breast cancer patients with pN0(i+) and pN1(mi) sentinel nodes have high rate of nonsentinel node metastases. J Am Coll Surg. 2005;200:323–7.PubMedCrossRef
13.
Ozmen V, Karanlik H, Cabioglu N, et al. Factors predicting the sentinel and non-sentinel lymph node metastases in breast cancer. Breast Cancer Res Treat. 2006;95:1–6.PubMedCrossRef
14.
Reynolds C, Mick R, Donohue JH, et al. Sentinel lymph node biopsy with metastasis: can axillary dissection be avoided in some patients with breast cancer? J Clin Oncol. 1999;17:1720–6.PubMed
15.
Saidi RF, Dudrick PS, Remine SG, Mittal VK. Nonsentinel lymph node status after positive sentinel lymph node biopsy in early breast cancer. Am Surg. 2004;70:101–5.PubMed
16.
Stitzenberg KB, Meyer AA, Stern SL, et al. Extracapsular extension of the sentinel lymph node metastasis: a predictor of nonsentinel node tumor burden. Ann Surg. 2003;237:607–12.PubMedCrossRef
17.
Travagli JP, Atallah D, Mathieu MC, et al. Sentinel lymphadenectomy without systematic axillary dissection in breast cancer patients: predictors of non-sentinel lymph node metastasis. Eur J Surg Oncol. 2003;29:403–6.PubMedCrossRef
18.
Turner RR, Chu KU, Qi K, et al. Pathologic features associated with nonsentinel lymph node metastases in patients with metastatic breast carcinoma in a sentinel lymph node. Cancer. 2000;89:574–81.PubMedCrossRef
19.
van der Loo EM, Hop WC, Tervoort MA, de Graaf PW. [Very slight chance of other metastases in axillary nodes of breast cancer patients with a small sentinel node metastasis without extranodal tumor growth]. Ned Tijdschr Geneeskd. 2004;148:938–43.PubMed
20.
van Iterson V, Leidenius M, Krogerus L, von SK. Predictive factors for the status of non-sentinel nodes in breast cancer patients with tumor positive sentinel nodes. Breast Cancer Res Treat. 2003;82:39–45.PubMedCrossRef
21.
Viale G, Maiorano E, Pruneri G, et al. Predicting the risk for additional axillary metastases in patients with breast carcinoma and positive sentinel lymph node biopsy. Ann Surg. 2005;241:319–25.PubMedCrossRef
22.
Wada N, Imoto S, Yamauchi C, Hasebe T, Ochiai A. Predictors of tumour involvement in remaining axillary lymph nodes of breast cancer patients with positive sentinel lymph node. Eur J Surg Oncol. 2006;32:29–33.PubMedCrossRef
23.
Weiser MR, Montgomery LL, Tan LK, et al. Lymphovascular invasion enhances the prediction of non-sentinel node metastases in breast cancer patients with positive sentinel nodes. Ann Surg Oncol. 2001;8:145–9.PubMedCrossRef
24.
Wong SL, Edwards MJ, Chao C, et al. Predicting the status of the nonsentinel axillary nodes: a multicenter study. Arch Surg. 2001;136:563–8.PubMedCrossRef
25.
Zavagno G, De Salvo GL, Bozza F, et al. Number of metastatic sentinel nodes as predictor of axillary involvement in patients with breast cancer. Breast Cancer Res Treat. 2004;86:171–9.PubMedCrossRef
26.
Van Zee KJ, Manasseh DM, Bevilacqua JL, et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol. 2003;10:1140–51.PubMedCrossRef
27.
van la Parra RF, Ernst MF, Barneveld PC, broekman JM, Rutten MJ, Bosscha K. The value of sentinel lymph node biopsy in ductal carcinoma in situ (DCIS) and DCIS with microinvasion of the breast. Eur J Surg Oncol. 2007.
28.
Barranger E, Coutant C, Flahault A, Delpech Y, Darai E, Uzan S. An axilla scoring system to predict non-sentinel lymph node status in breast cancer patients with sentinel lymph node involvement. Breast Cancer Res Treat. 2005;91:113–9.PubMedCrossRef
29.
Cripe MH, Beran LC, Liang WC, Sickle-Santanello BJ. The likelihood of additional nodal disease following a positive sentinel lymph node biopsy in breast cancer patients: validation of a nomogram. Am J Surg. 2006;192:484–7.PubMedCrossRef
30.
Degnim AC, Reynolds C, Pantvaidya G, et al. Nonsentinel node metastasis in breast cancer patients: assessment of an existing and a new predictive nomogram. Am J Surg. 2005;190:543–50.PubMedCrossRef
31.
Houvenaeghel G, Nos C, Mignotte H, et al. Micrometastases in sentinel lymph node in a multicentric study: predictive factors of nonsentinel lymph node involvement. Groupe des Chirurgiens de la Federation des Centres de Lutte Contre le Cancer. J Clin Oncol. 2006;24:1814–22.PubMedCrossRef
32.
Nos C, Harding-MacKean C, Freneaux P, et al. Prediction of tumour involvement in remaining axillary lymph nodes when the sentinel node in a woman with breast cancer contains metastases. Br J Surg. 2003;90:1354–60.PubMedCrossRef
33.
Rivers AK, Griffith KA, Hunt KK, et al. Clinicopathologic features associated with having four or more metastatic axillary nodes in breast cancer patients with a positive sentinel lymph node. Ann Surg Oncol. 2006;13:36–44.PubMedCrossRef
34.
Sachdev U, Murphy K, Derzie A, Jaffer S, Bleiweiss IJ, Brower S. Predictors of nonsentinel lymph node metastasis in breast cancer patients. Am J Surg. 2002;183:213–7.PubMedCrossRef
35.
Schrenk P, Konstantiniuk P, Wolfl S, et al. Prediction of non-sentinel lymph node status in breast cancer with a micrometastatic sentinel node. Br J Surg. 2005;92:707–13.PubMedCrossRef
36.
Alran S, De RY, Fourchotte V, et al. Validation and limitations of use of a breast cancer nomogram predicting the likelihood of non-sentinel node involvement after positive sentinel node biopsy. Ann Surg Oncol. 2007;14:2195–201.PubMedCrossRef
37.
Cripe MH, Beran LC, Liang WC, Sickle-Santanello BJ. The likelihood of additional nodal disease following a positive sentinel lymph node biopsy in breast cancer patients: validation of a nomogram. Am J Surg. 2006;192:484–7.PubMedCrossRef
38.
Dauphine CE, Haukoos JS, Vargas MP, Isaac NM, Khalkhali I, Vargas HI. Evaluation of three scoring systems predicting non sentinel node metastasis in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol. 2007;14:1014–9.PubMedCrossRef
39.
Degnim AC, Reynolds C, Pantvaidya G, et al. Nonsentinel node metastasis in breast cancer patients: assessment of an existing and a new predictive nomogram. Am J Surg. 2005;190:543–50.PubMedCrossRef
40.
Klar M, Jochmann A, Foeldi M, et al. The MSKCC nomogram for prediction the likelihood of non-sentinel node involvement in a German breast cancer population. Breast Cancer Res Treat. 2008;112(3):523–31.PubMedCrossRef
41.
Kocsis L, Svebis M, Boross G, et al. Use and limitations of a nomogram predicting the likelihood of non-sentinel node involvement after a positive sentinel node biopsy in breast cancer patients. Am Surg. 2004;70:1019–24.PubMed
42.
Kohrt HE, Olshen RA, Bermas HR, et al. New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients. BMC Cancer. 2008;8:66.PubMedCrossRef
43.
Lambert LA, Ayers GD, Hwang RF, et al. Validation of a breast cancer nomogram for predicting nonsentinel lymph node metastases after a positive sentinel node biopsy. Ann Surg Oncol. 2006;13:310–20.PubMedCrossRef
44.
Pal A, Provenzano E, Duffy SW, Pinder SE, Purushotham AD. A model for predicting non-sentinel lymph node metastatic disease when the sentinel lymph node is positive. Br J Surg. 2008;95:302–9.PubMedCrossRef
45.
Ponzone R, Maggiorotto F, Mariani L, et al. Comparison of two models for the prediction of nonsentinel node metastases in breast cancer. Am J Surg. 2007;193:686–92.PubMedCrossRef
46.
Smidt ML, Kuster DM, van der Wilt GJ, Thunnissen FB, Van Zee KJ, Strobbe LJ. Can the Memorial Sloan-Kettering Cancer Center nomogram predict the likelihood of nonsentinel lymph node metastases in breast cancer patients in the Netherlands? Ann Surg Oncol. 2005;12:1066–72.PubMedCrossRef
47.
Soni NK, Carmalt HL, Gillett DJ, Spillane AJ. Evaluation of a breast cancer nomogram for prediction of non-sentinel lymph node positivity. Eur J Surg Oncol. 2005;31:958–64.PubMedCrossRef
48.
Specht MC, Kattan MW, Gonen M, Fey J, Van Zee KJ. Predicting nonsentinel node status after positive sentinel lymph biopsy for breast cancer: clinicians versus nomogram. Ann Surg Oncol. 2005;12:654–9.PubMedCrossRef
49.
Zgajnar J, Perhavec A, Hocevar M, et al. Low performance of the MSKCC nomogram in preoperatively ultrasonically negative axillary lymph node in breast cancer patients. J Surg Oncol. 2007;96:547–53.PubMedCrossRef
50.
Hosmer DW, Lemeshow S. Applied logistic regression. 2nd ed. New York: Wiley; 2000.
51.
Goyal A, Newcombe RG, Chhabra A, Mansel RE. Factors affecting failed localisation and false-negative rates of sentinel node biopsy in breast cancer—results of the ALMANAC validation phase. Breast Cancer Res Treat. 2006;99:203–8.PubMedCrossRef
52.
Martin RC, Chagpar A, Scoggins CR, et al. Clinicopathologic factors associated with false-negative sentinel lymph-node biopsy in breast cancer. Ann Surg. 2005;241:1005–12.PubMedCrossRef
53.
Wong SL, Edwards MJ, Chao C, et al. Sentinel lymph node biopsy for breast cancer: impact of the number of sentinel nodes removed on the false-negative rate. J Am Coll Surg. 2001;192:684–9.PubMedCrossRef
54.
Truong PT, Bernstein V, Wai E, Chua B, Speers C, Olivotto IA. Age-related variations in the use of axillary dissection: a survival analysis of 8038 women with T1–ST2 breast cancer. Int J Radiat Oncol Biol Phys. 2002;54:794–803.PubMedCrossRef
Metadata
Title
Validation of a Nomogram to Predict the Risk of Nonsentinel Lymph Node Metastases in Breast Cancer Patients with a Positive Sentinel Node Biopsy: Validation of the MSKCC Breast Nomogram
Authors
R. F. D. van la Parra, MD
M. F. Ernst, MD, PhD
J. L. B. Bevilacqua, MD, PhD
S. J. J. Mol, MD
K. J. Van Zee, MS, MD
J. M. Broekman, MD, PhD
K. Bosscha, MD, PhD
Publication date
01-05-2009
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 5/2009
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-009-0359-y

Other articles of this Issue 5/2009

Annals of Surgical Oncology 5/2009 Go to the issue

Bone and Soft Tissue Sarcomas

Role of Sentinel Lymph Node Biopsy in the Staging of Synovial, Epithelioid, and Clear Cell Sarcomas

Healthcare Policy and Outcomes

Use of a Novel, Web-Based Educational Platform Facilitates Intraoperative Training in a Surgical Oncology Fellowship Program

Gastrointestinal Oncology

Identification of High-Risk Stage II Colorectal Tumors by Combined Analysis of the NDRG1 Gene Expression and the Depth of Tumor Invasion

Gastrointestinal Oncology

Therapeutic Value of Lymph Node Dissection in Advanced Gastric Cancer with Macroscopic Duodenum Invasion: Is the Posterior Pancreatic Head Lymph Node Dissection Beneficial?

Head and Neck Oncology

Decrease in Hemoglobin Levels Following Surgery Influences the Outcome in Head and Neck Cancer Patients Treated with Accelerated Postoperative Radiotherapy

Breast Oncology

Measurement of Uterine Radiation Exposure from Lymphoscintigraphy Indicates Safety of Sentinel Lymph Node Biopsy during Pregnancy